VDAC-Targeted Drugs Affecting Cytoprotection and Mitochondrial Physiology in Cerebrovascular and Cardiovascular Diseases

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|24|40|4419-4434

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.24, Iss.40, 2018-01, pp. : 4419-4434

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Minocycline Mediated Mitochondrial Cytoprotection: Premises for Therapy of Cerebrovascular and Neurodegenerative Diseases

By  

Current Drug Targets, Vol. 14, Iss. 1, 2013-01 ,pp. : 47-55

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted Drug Delivery for Cardiovascular and Cerebrovascular Diseases

By  

Current Drug Targets, Vol. 17, Iss. 4, 2016-03 ,pp. : 467-474

Bentham Science Publishers

Access to resources Recommend Favorite

Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes

By  

Current Pharmaceutical Design, Vol. 17, Iss. 20, 2011-07 ,pp. : 1986-2001

Bentham Science Publishers

Access to resources Recommend Favorite

Drugs Affecting Homocysteine Metabolism: Impact on Cardiovascular Risk

By Desouza C.   Keebler M.   McNamara D.B.   Fonseca V.  

Drugs, Vol. 62, Iss. 4, 2002-04 ,pp. : 605-616

Adis International

Access to resources Recommend Favorite

Drugs and mitochondrial diseases: 40 queries and answers

By Mancuso Michelangelo   Orsucci Daniele   Filosto Massimiliano   Simoncini Costanza   Siciliano Gabriele  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 4, 2012-03 ,pp. : 527-543

Informa Healthcare

Access to resources Recommend Favorite